Rafael Holdings

Update in progress

RFL (NYSE)

Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical companies and medical devices in the United States and Israel. It operates in three segments: Healthcare, Infusion Technology, and Real Estate. The company develops therapies that target cancer metabolism. Lead candidates include Trappsol Cyclo (NPC1, Phase 3) and CPI-613 (devimistat, Phase II), plus Promitil (Phase 1 completed). It also develops surgical devices, including arthroscopy tools for Carpal Tunnel. Based in Newark, NJ, founded 2017.